BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Increased DNA Polymerase Fidelity of the Lamivudine Resistant Variants of Human Hepatitis B Virus DNA Polymerase

  • Hong, Young-Bin (Division of Genetic Disease, Korean National Institute of Health) ;
  • Choi, Yong-Wook (School of Biological Science, Seoul National University) ;
  • Jung, Gu-Hung (School of Biological Science, Seoul National University)
  • Published : 2004.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Although efficient antiviral lamivudine is used for HBV-infected patients, a prolonged treatment with nucleoside analogs often results in lamivudine-resistant variants. In this study, we evaluated the fidelity of the lamivudine-resistant variants. The FLAG-tagged wild-type (FPolE) and Met550 variants (FPolE/M550A, M550V, and M550I) of HBV DNA polymerases were expressed in insect cells then purified. Like many other reverse transcriptases, no $3'{\rightarrow}5'$ exonuclease activity was detected in the HBV DNA polymerase. Since there is no proofreading activity, then the use of the site-specific nucleotide misincorporation method is beneficial. From the $f_{ins}$ value analysis, it is evident that M550I and M550V exhibit higher fidelity values than the wild-type HBV DNA polymerase, while M550A exhibits similar fidelity values. It is therefore suggested that lamivudine resistance comes from the stringency to dNTP binding and the discrimination of dCTP and lamivudine in M550V and M550I.

Keywords

References

  1. Allen, M. I., Deslauriers, M., Andrew, C. W., Tipple, G. A., Walters, K. A., Tyrrell, D. L., Brown, N. and Condreay, L. D. (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27, 1670-1677. https://doi.org/10.1002/hep.510270628
  2. Bakhanashvili, M., Avidan, O. and Hizi, A. (1996) Mutational studies of human immunodeficiency virus type 1 reverse transcriptase: the involvement of residues 183 and 184 in the fidelity of DNA synthesis. FEBS Lett. 391, 257-262 https://doi.org/10.1016/0014-5793(96)00747-8
  3. Bartholomew, M. M., Jansen, R. W., Jeffers, L. J., Reddy, K. R., Johnson, L. C., Bunzendahl, H., Condreay, L. D., Tzakis, A. G., Schiff, E. R. and Brown, N. A. (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349, 20-22. https://doi.org/10.1016/S0140-6736(96)02266-0
  4. Beasley, R. P., Hwang, L. Y., Lin, C. C. and Chien, C. S. (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2, 1129-1133.
  5. Boosalis, M. S., Petruska, J. and Goodman, M. F. (1987) DNA polymerase insertion fidelity. Gel assay for site-specific kinetics. J. Biol. Chem. 262, 14689-14696.
  6. Buti, M., Jardi, R., Cotrina, M., Rodirquez-Frias, F., Esteban, R. and Guardia, J. (1998) Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J. Hepatol. 28, 510-513.
  7. Coates, J. A., Cammack, N., Jenkinson, H. J., Jowett, A. J., Jowett, M. I., Pearson, B. A., Penn, C. R., Rouse, P. L., Viner, K. C. and Cameron, J. M. (1992) (-)-2'-deoxy-3'-thiacytinine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36, 733-739. https://doi.org/10.1128/AAC.36.4.733
  8. Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G. and Arnold, E. (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to Lamivudine(3TC) and Emtricitabine(FTC). J. Virol. 75, 4771-4779. https://doi.org/10.1128/JVI.75.10.4771-4779.2001
  9. De Clercq, E. (1999) Perspectives for the treatment of hepatitis B virus infections. Int. J. Antimicrob. Agents 12, 81-95. https://doi.org/10.1016/S0924-8579(99)00060-6
  10. Dienstag, J. L., Schiff, R., Wright, T. L., Perrillo, R. P., Hann, H. W., Goodman, Z., Crowther, L., Condreay, L.D., Woessner, M., Rubin, M. and Brown, N. A. (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256-1263. https://doi.org/10.1056/NEJM199910213411702
  11. Echols, H. and Goodman, M. F. (1991) Fidelity mechanisms in DNA replication. Annu. Rev. Biochem. 60, 477-511. https://doi.org/10.1146/annurev.bi.60.070191.002401
  12. Hamburgh, M. E., Drosopoulos, W. C. and Prasad, V. R. (1998) The influence of 3TC resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency. Nucleic Acid Res. 26, 4389-4394. https://doi.org/10.1093/nar/26.19.4389
  13. Harrison, T. J. (1996) Genetic variation in hepatitis B virus. Eur. J. Gastroenterol. Hepatol. 8, 306-311. https://doi.org/10.1097/00042737-199604000-00003
  14. Hubner, A., Kruhoffer, M., Grosse, F. and Krauss, G. (1992) Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural RNA. J. Mol. Biol. 223, 595-600. https://doi.org/10.1016/0022-2836(92)90975-P
  15. Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X. Jr., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., Hizi, A., Hughes, S. H. and Arnold, E. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90, 6320-6324. https://doi.org/10.1073/pnas.90.13.6320
  16. Jardi, R., Buti, M., Rodriguez-Frias, F., Cotrina, M., Costa, X., Pascual, C., Esteban, R. and Guardia, J. (1999) Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods 83, 181-187. https://doi.org/10.1016/S0166-0934(99)00125-1
  17. Jarvis, B. and Faulds, D. (1999) Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58, 101-141. https://doi.org/10.2165/00003495-199958010-00015
  18. Kaushik, N., Chowdhury, K., Pandey, V. N. and Modak, M. J. (2000) Valine of the YVDD motif of moloney murine leukemia virus reverse transcriptase: role in the fidelity of DNA synthesis. Biochemistry 39, 5155-5165. https://doi.org/10.1021/bi992223b
  19. Kim, S. I., Kim, S. -J., Leem, S. -H., Oh, K. -H., Kim, S. and Park, Y. -M. (2001) Site-directed mutagenesis of two cysteines (155, 202) in catechol 1,2-dioxygenase I1 of Acinetobacter lwoffii K24. J. Biochem. Mol. Biol. 34, 172-175.
  20. Kunkel, T. A. (1992) DNA replication fidelity. J. Biol. Chem. 267, 18251-18254.
  21. Lai, C. L., Chien, R. N., Leung, N. W., Chang, T. T., Guan, R., Tai, D. I., Ng, K. Y., Wu, P. C., Dent, J. C., Barber, J., Stephenson, S. L. and Gray, D. F. (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61-69. https://doi.org/10.1056/NEJM199807093390201
  22. Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G. M. and Harrison, T. J. (1996) Selection of utations in the hepatitis B virus polymerase during therapy of ransplant recipients with lamivudine. Hepatology 24, 711-713. https://doi.org/10.1002/hep.510240339
  23. Lok, A. S. (2000) Hepatitis B infection: pathogenesis and management. J. Hepatol. 32, 89-97.
  24. Mendelman, L. V., Boosalis, M. S., Petruska, J. and Goodman, M. F. (1989) Nearest neighbor influences on DNA polymerase insertion fidelity. J. Biol. Chem. 264, 14415-14423.
  25. Mendelman, L. V., Petruska, J. and Goodman, M. F. (1990) Base mispair extension kinetics. Comparison of DNA polymerase alpha and reverse transcriptase. J. Biol. Chem. 265, 2338-2346.
  26. Ono, S. K., Kato, N., Shiratori, Y., Kato, J., Goto, T., Schinazi, R. F., Carrilho, F. J. and Omata, M. (2001) The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107, 449-455. https://doi.org/10.1172/JCI11100
  27. Oude Essink, B. B., Back, N. K. and Berkhout, B. (1997) Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res. 25, 3212-3217. https://doi.org/10.1093/nar/25.16.3212
  28. Pandey, V. N., Kaushik, N., Rege, N., Sarafianos, S. G., Yandav, P. N. and Modak, M. J. (1996) Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 35, 2168-2179. https://doi.org/10.1021/bi9516642
  29. Park, S. G. and Jung, G. (2001) Human hepatitis B virus polymerase interacts with the molecular chaperonin Hsp60. J. Virol. 75, 6962-6968. https://doi.org/10.1128/JVI.75.15.6962-6968.2001
  30. Park, I. and David, J. I. (2002) Mutations within the putative active site of heterodimeric deoxyguanosine kinase block the allosteric activation of the deoxyadenosine kinase subunit. J. Biochem. Mol. Biol. 35, 244-247. https://doi.org/10.5483/BMBRep.2002.35.2.244
  31. Preston, B. D., Poiesz, B. J. and Loeb, L. A. (1988) Fidelity of HIV-1 reverse transcriptase. Science 242, 1168-1171. https://doi.org/10.1126/science.2460924
  32. Randall, S. K., Eritja, R., Kaplan, B. E., Petruska, J. and Goodman, M. F. (1987) Nucleotide insertion kinetics opposite abasic lesions in DNA. J. Biol. Chem. 262, 6864-6870.
  33. Rho, H. M., Kim, K., Hyun, S. W. and Kim, Y. S. (1989) The nucleotide sequence and reading frames of a mutant hepatitis B virus subtype adr. Nucleic Acids Res. 17, 21-24.
  34. Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A. and Pastore, G. (2000) Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 32, 300-306. https://doi.org/10.1016/S0168-8278(00)80076-8
  35. Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C. and Christopherson, C., et al. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171, 1411-1419. https://doi.org/10.1093/infdis/171.6.1411
  36. Williams, K. J. and Loeb, L. A. (1992) Retroviral reverse transcriptases: error frequencies and mutagenesis. Curr. Top. Microbiol. Immunol. 176, 165-180.
  37. Yu, H. and Goodman, M. F. (1992) Comparison of HIV-1 and avian myeloblastosis virus reverse transcriptase fidelity on RNA and DNA templates. J. Biol. Chem. 267, 10888-10896.
  38. Zoulim, F. (1999) Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral. Res. 44, 1-30. https://doi.org/10.1016/S0166-3542(99)00056-X

Cited by

  1. HBV drug resistance: Mechanisms, detection and interpretation vol.44, pp.3, 2006, https://doi.org/10.1016/j.jhep.2006.01.001
  2. Mechanisms of viral mutation vol.73, pp.23, 2016, https://doi.org/10.1007/s00018-016-2299-6
  3. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance vol.48, pp.3, 2008, https://doi.org/10.1002/hep.22386